Retreatment Strategies for Patients Failing First-Line Therapy
Source: Advanced Topics in Hepatitis C Management: Tools for Nurse Practitioners and Physician Assistants

Module

HoChong Gilles, RN, MS, FNP, reviews clinical management options for patients with chronic HCV infection who fail interferon-based therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify causes of nonresponse and relapse to hepatitis C virus (HCV) therapy
  • Describe definitions of response during HCV therapy and key time points for monitoring response to treatment
  • Discuss diagnosis and management of common adverse effects of HCV therapy and strategies for monitoring patient adherence
  • Recall strategies for selecting optimal treatment for patients based on their baseline factors and previous course of therapy

Topics covered include:

  • Introduction
  • Treatment Response Patterns
  • Factors Contributing to Treatment Failure
  • Comorbidities as Predictors of Nonresponse
  • Other Factors Associated With Nonresponse
  • Assessing Factors Related to Nonresponse Before Retreatment
  • Retreatment Options in Nonresponders and Relapsers
  • Summary: Implications for Clinical Practice
 

Program Directors

  • Michael W. Fried
    MD

Faculty

  • HoChong Gilles
    RN, MS, FNP

Credit Information

  • Release Date:
    June 28, 2007
  • Expiration Date:
    June 27, 2008
  • Physicians:
    maximum of 1.5 AMA PRA Category 1 Credits
  • Registered Nurses:
    1.5 Nursing contact hours
  • Physician Assistants:
    maximum of 1.5 hours of AAPA Category I (Preapproved) credits
  • Prioritizing Patients for HCV Therapy: The Case for Treating Before Advanced Disease

    Nancy Reau MD - 9/23/2014    2 comments / Last Comment: 10/1/2014
    Despite remarkable advances in curative treatments for HCV, many patients are being denied insurance coverage, as priority access to these costly medications is given to those with advanced disease.
  • Delivering on the Promise: Maximizing SVR in the Real World

    Jordan J. Feld MD, MPH - 10/6/2014    
    Delivering the successes of recent HCV therapy trials to the real world will take some work, but here is how it can be achieved.
  • My Take on the Guidance From AASLD/IDSA for Treating Interferon-Ineligible Patients With Genotype 1 HCV Infection

    Paul Y. Kwo MD - 10/9/2014    
    Historically, evaluating patients for interferon eligibility was critical. Today, interferon-free regimens are evolving and soon they will be standard practice for even the most difficult-to-treat disease.
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014    4 comments / Last Comment: 9/18/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
  • How Does the AASLD/IDSA HCV Guidance Weigh in on Management of HIV Coinfection?

    Douglas T. Dieterich MD - 10/9/2014    
    There is great interest in offering coinfected patients the same opportunity for cure as monoinfected patients. The AASLD/IDSA guidance has developed recommendations aimed at maximizing cure in different populations of coinfected individuals.